Calgary, Alberta (Newsfile Corp. - March 2, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has signed a binding term sheet
Calgary, Alberta (Newsfile Corp. - June 11, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it closed its previously announced
Hemostemix Announces the TSX Venture s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update May 29, 2021 Calgary,. | May 30, 2021
(0)
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Calgary, Alberta (Newsfile Corp. - May 29, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) ( Hemostemix or the Company ) is pleased to announce that it has obtained preliminary approval from the TSX Venture Exchange to close a $2,500,000 convertible debenture order from a director for Debenture Units priced at $0.40 per Unit as detailed below. On May 28, 2021, Hemostemix filed its Financial Statements and Management Discussion and Analysis for the period ending March 31, 2020 on SEDAR. This financing segregates the litigation risk from the equity risk and enables the Company to move forward with its business plans, stated Thomas Smeenk, CEO.
Hemostemix Inc : Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.